BR9914116A - Composições e métodos para imunoterapia especìfica de wt1 - Google Patents
Composições e métodos para imunoterapia especìfica de wt1Info
- Publication number
- BR9914116A BR9914116A BR9914116-7A BR9914116A BR9914116A BR 9914116 A BR9914116 A BR 9914116A BR 9914116 A BR9914116 A BR 9914116A BR 9914116 A BR9914116 A BR 9914116A
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- methods
- polypeptide
- specific immunotherapy
- cell
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4242—Transcription factors, e.g. SOX or c-MYC
- A61K40/4243—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/164,223 US7063854B1 (en) | 1998-09-30 | 1998-09-30 | Composition and methods for WTI specific immunotherapy |
| US27648499A | 1999-03-25 | 1999-03-25 | |
| PCT/US1999/022819 WO2000018795A2 (en) | 1998-09-30 | 1999-09-30 | Compositions and methods for wt1 specific immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9914116A true BR9914116A (pt) | 2002-01-15 |
Family
ID=26860363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9914116-7A BR9914116A (pt) | 1998-09-30 | 1999-09-30 | Composições e métodos para imunoterapia especìfica de wt1 |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1117687B1 (https=) |
| JP (3) | JP4243792B2 (https=) |
| KR (1) | KR100752065B1 (https=) |
| CN (1) | CN100486995C (https=) |
| AR (1) | AR021849A1 (https=) |
| AT (1) | ATE399179T1 (https=) |
| AU (1) | AU6407899A (https=) |
| BR (1) | BR9914116A (https=) |
| CA (1) | CA2349442C (https=) |
| CZ (1) | CZ20011144A3 (https=) |
| DE (1) | DE69938970D1 (https=) |
| ES (1) | ES2310052T3 (https=) |
| HK (1) | HK1039782B (https=) |
| HU (1) | HUP0103598A3 (https=) |
| IL (2) | IL142216A0 (https=) |
| MX (1) | MXPA01003344A (https=) |
| MY (1) | MY139226A (https=) |
| NO (1) | NO325839B1 (https=) |
| NZ (1) | NZ510600A (https=) |
| PL (1) | PL201881B1 (https=) |
| RU (1) | RU2237674C2 (https=) |
| SA (1) | SA00200872B1 (https=) |
| TR (1) | TR200101482T2 (https=) |
| TW (1) | TWI285648B (https=) |
| WO (1) | WO2000018795A2 (https=) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2243235C (en) | 1996-01-17 | 2010-08-10 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| AU4932199A (en) * | 1998-07-31 | 2000-02-21 | Haruo Sugiyama | Cancer antigens based on tumor suppressor gene wt1 product |
| US7063854B1 (en) | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
| US20030235557A1 (en) * | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US7329410B1 (en) | 1998-09-30 | 2008-02-12 | Corixa Corporation | Compositions and method for WT1 specific immunotherapy |
| US7901693B2 (en) | 1998-09-30 | 2011-03-08 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US20030072767A1 (en) * | 1998-09-30 | 2003-04-17 | Alexander Gaiger | Compositions and methods for WT1 specific immunotherapy |
| US7655249B2 (en) | 1998-09-30 | 2010-02-02 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US7144581B2 (en) | 2000-10-09 | 2006-12-05 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US7115272B1 (en) | 1998-09-30 | 2006-10-03 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| GB9823897D0 (en) * | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
| WO2001025273A2 (en) * | 1999-10-04 | 2001-04-12 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
| CA2401070A1 (en) * | 2000-02-22 | 2001-08-30 | Corixa Corporation | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| JP4592641B2 (ja) * | 2000-05-24 | 2010-12-01 | 治夫 杉山 | Ｗｔ１関連疾患の検査方法 |
| JP3846199B2 (ja) | 2000-05-24 | 2006-11-15 | 治夫 杉山 | Ｗｔ１関連疾患の検査方法 |
| EP1371664B1 (en) * | 2001-03-22 | 2008-01-09 | International Institute of Cancer Immunology, Inc. | Wti modified peptide |
| ATE494905T1 (de) * | 2001-06-29 | 2011-01-15 | Chugai Pharmaceutical Co Ltd | Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom |
| US7553494B2 (en) | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
| US20050002951A1 (en) * | 2001-09-28 | 2005-01-06 | Haruo Sugiyama | Novel method of inducing antigen-specific t cells |
| JP5230891B2 (ja) * | 2001-09-28 | 2013-07-10 | 株式会社癌免疫研究所 | 抗原特異的ｔ細胞の新規な誘導方法 |
| WO2003106682A1 (ja) * | 2002-06-12 | 2003-12-24 | 中外製薬株式会社 | Ｈｌａ−ａ２４拘束性癌抗原ペプチド |
| WO2004024175A1 (ja) * | 2002-09-12 | 2004-03-25 | Haruo Sugiyama | 癌抗原ペプチド製剤 |
| ES2331305T3 (es) * | 2002-09-20 | 2009-12-29 | International Institute Of Cancer Immunology, Inc. | Peptidos de wt1 de tipo sustituido. |
| ES2332590T3 (es) * | 2003-01-15 | 2010-02-09 | International Institute Of Cancer Immunology, Inc. | Dimero peptidico. |
| WO2005001117A1 (ja) * | 2003-06-27 | 2005-01-06 | Haruo Sugiyama | Ｗｔ１ワクチン適応患者の選択方法 |
| KR101213015B1 (ko) * | 2003-11-05 | 2012-12-26 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드 |
| PT1731605E (pt) * | 2004-03-31 | 2010-04-14 | Int Inst Cancer Immunology Inc | Péptidos antigénicos de cancro derivados de wt1 |
| EP1657250A1 (en) * | 2004-11-11 | 2006-05-17 | Charité - Universitätsmedizin Berlin | HLA-A *01-binding T-cell epitope of WT1 |
| RU2286146C1 (ru) * | 2005-04-12 | 2006-10-27 | Ростовский научно-исследовательский онкологический институт МЗ РФ | Способ лечения церебральных метастазов генерализованной меланомы кожи |
| RU2301061C2 (ru) * | 2005-04-28 | 2007-06-20 | Ростовский научно-исследовательский онкологический институт МЗ РФ | Способ лечения генерализованной меланомы кожи |
| CA2631292C (en) | 2005-11-30 | 2014-05-06 | International Institute Of Cancer Immunology, Inc. | Derivatised wt1 cancer antigen peptides and their use |
| AU2007218649B2 (en) | 2006-02-22 | 2013-01-10 | International Institute Of Cancer Immunology, Inc. | HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same |
| KR101543622B1 (ko) * | 2006-10-17 | 2015-08-11 | 온코세라피 사이언스 가부시키가이샤 | Ｍｐｈｏｓｐｈ1 또는 ｄｅｐｄｃ1 폴리펩티드를 발현하는 암에 대한 펩티드 백신 |
| EP2341142B8 (en) | 2006-12-28 | 2015-01-14 | International Institute of Cancer Immunology, Inc. | HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising same |
| BRPI0808084A2 (pt) | 2007-02-27 | 2014-07-22 | Int Inst Cancer Immunology Inc | Método para ativação de células t auxiliadoras e composição para uso no método. |
| WO2008106551A2 (en) * | 2007-02-28 | 2008-09-04 | The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. | Brachyury polypeptides and methods for use |
| KR101773690B1 (ko) | 2007-03-05 | 2017-08-31 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 |
| EP2216041A4 (en) * | 2007-11-20 | 2012-10-24 | Nec Corp | METHOD OF INDUCING A CYTOTOXIC T-CELL, CYTOTOXIC T-CELL INDUCTOR AND PHARMACEUTICAL COMPOSITION, AND VACCINE WITH THE INDUCTOR |
| CA2940962C (en) * | 2007-12-05 | 2018-07-24 | International Institute Of Cancer Immunology, Inc. | Cancer vaccine composition |
| AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
| CN110542754A (zh) * | 2009-05-19 | 2019-12-06 | 迈阿密大学 | 用于体外抗原呈递、评估疫苗功效及生物制剂和药物的免疫毒性的组合物、试剂盒和方法 |
| KR20140009168A (ko) | 2010-10-05 | 2014-01-22 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 헬퍼 ｔ 세포의 활성화 방법 |
| MX2013011363A (es) * | 2011-04-01 | 2014-04-25 | Sloan Kettering Inst Cancer | Anticuerpos para peptidos citosolicos. |
| CA2839663A1 (en) | 2011-06-28 | 2013-01-03 | International Institute Of Cancer Immunology, Inc. | Receptor gene for peptide cancer antigen-specific t cell |
| JP6163486B2 (ja) | 2012-07-02 | 2017-07-12 | 大日本住友製薬株式会社 | 癌抗原ペプチド経皮剤 |
| SG10201705028WA (en) | 2012-12-17 | 2017-07-28 | Otsuka Pharma Co Ltd | Method for activating helper t cell |
| EP2974734B1 (en) | 2013-03-12 | 2018-10-10 | Sumitomo Dainippon Pharma Co., Ltd. | Liquid aqueous composition |
| SG11201507883SA (en) | 2013-03-29 | 2015-10-29 | Sumitomo Dainippon Pharma Co Ltd | Wt1-antigen peptide conjugate vaccine |
| WO2014157704A1 (ja) | 2013-03-29 | 2014-10-02 | 大日本住友製薬株式会社 | Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン |
| KR20160007579A (ko) | 2013-05-13 | 2016-01-20 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 면역요법의 임상 효과의 예측법 |
| CN106170297A (zh) * | 2013-09-20 | 2016-11-30 | 纪念斯隆-凯特琳癌症中心 | 用于wt‑1‑阳性疾病的组合/辅助疗法 |
| JP6005305B2 (ja) | 2014-02-26 | 2016-10-12 | テラ株式会社 | Ｗｔ１抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤 |
| ES2805094T3 (es) * | 2014-12-11 | 2021-02-10 | Int Inst Cancer Immunology Inc | Inmunoterapia WT1 para enfermedad angiogénica intraocular |
| JP6947720B2 (ja) * | 2015-09-10 | 2021-10-13 | メモリアル スローン ケタリング キャンサー センター | Ｔ細胞療法による多発性骨髄腫及び形質細胞白血病の治療方法 |
| SMT202200370T1 (it) * | 2015-11-20 | 2022-11-18 | Memorial Sloan Kettering Cancer Center | Composizione per il trattamento del cancro |
| CN105254760B (zh) * | 2015-11-21 | 2018-08-17 | 福州迈新生物技术开发有限公司 | 一株分泌抗wt1蛋白的单克隆抗体及其应用 |
| US12383608B2 (en) | 2016-11-30 | 2025-08-12 | Sumitomo Pharma Co., Ltd. | WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides |
| JPWO2018181648A1 (ja) | 2017-03-30 | 2020-02-13 | 大日本住友製薬株式会社 | Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体 |
| BR112019020959A2 (pt) * | 2017-04-10 | 2020-05-05 | Immatics Biotechnologies Gmbh | peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer |
| MX2020006119A (es) | 2017-12-21 | 2020-08-24 | Hoffmann La Roche | Anticuerpos de union a hla-a2/wt1. |
| CN109758575B (zh) * | 2018-02-14 | 2022-08-30 | 上海微球生物科技有限公司 | 充分多样的双亲性mhc ii结合多肽、免疫载体微球及其制备方法和应用 |
| JP7162675B2 (ja) | 2018-09-28 | 2022-10-28 | 住友ファーマ株式会社 | 注射用組成物 |
| TWI875736B (zh) | 2019-02-28 | 2025-03-11 | 日商住友製藥股份有限公司 | 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法 |
| JP7153287B2 (ja) | 2020-05-12 | 2022-10-14 | 住友ファーマ株式会社 | 癌を処置するための医薬組成物 |
| WO2021231376A2 (en) * | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| CN111647066B (zh) * | 2020-07-01 | 2020-12-18 | 维肽瀛(上海)生物技术有限公司 | Wt1多肽肿瘤抑制剂 |
| KR102476515B1 (ko) * | 2020-09-11 | 2022-12-12 | 한국생명공학연구원 | 치주 질환 특이 항체 및 이의 용도 |
| KR20220034563A (ko) * | 2020-09-11 | 2022-03-18 | 한국생명공학연구원 | 신규 치주 질환 특이 항체 및 이의 용도 |
| MX2024001843A (es) | 2021-08-12 | 2024-05-16 | Int Inst Cancer Immunology Inc | Composición farmacéutica y método para tratar o prevenir cáncer. |
| EP4410304A4 (en) * | 2021-09-24 | 2025-08-27 | Cha Vaccine Res Institute Co Ltd | CANCER VACCINE COMPOSITION COMPRISING PEPTIDES DERIVED FROM A TUMOR-ASSOCIATED ANTIGEN, AND AN ADJUVANT CONSISTING OF A LIPOPEPTIDE AND AN IMMUNOACTIVE SUBSTANCE, AND USE THEREOF |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3393867B2 (ja) * | 1989-11-13 | 2003-04-07 | マサチユーセツツ・インステイテユート・オブ・テクノロジー | ウィルムス腫瘍遺伝子の位置決定と特徴付け |
| RU2100369C1 (ru) * | 1992-04-22 | 1997-12-27 | Варнер-Ламберт Компани | Производные пептида или их фармацевтически приемлемые соли |
| US5705159A (en) * | 1993-08-31 | 1998-01-06 | John Wayne Cancer Institute | Immunoreactive peptide sequence from a 43 KD human cancer antigen |
| US5622835A (en) * | 1994-04-28 | 1997-04-22 | The Wistar Institute Of Anatomy & Biology | WT1 monoclonal antibodies |
| WO1999058135A1 (en) * | 1998-05-11 | 1999-11-18 | The Salk Institute For Biological Studies | Compositions for the treatment of tumors, and uses thereof |
| AU4932199A (en) * | 1998-07-31 | 2000-02-21 | Haruo Sugiyama | Cancer antigens based on tumor suppressor gene wt1 product |
-
1999
- 1999-09-30 AR ARP990104969A patent/AR021849A1/es active IP Right Grant
- 1999-09-30 EP EP99951690A patent/EP1117687B1/en not_active Expired - Lifetime
- 1999-09-30 CA CA2349442A patent/CA2349442C/en not_active Expired - Fee Related
- 1999-09-30 ES ES99951690T patent/ES2310052T3/es not_active Expired - Lifetime
- 1999-09-30 KR KR1020017004049A patent/KR100752065B1/ko not_active Expired - Fee Related
- 1999-09-30 MX MXPA01003344A patent/MXPA01003344A/es not_active IP Right Cessation
- 1999-09-30 IL IL14221699A patent/IL142216A0/xx unknown
- 1999-09-30 CN CNB998133493A patent/CN100486995C/zh not_active Expired - Fee Related
- 1999-09-30 HU HU0103598A patent/HUP0103598A3/hu unknown
- 1999-09-30 RU RU2001111834A patent/RU2237674C2/ru not_active IP Right Cessation
- 1999-09-30 HK HK02100544.9A patent/HK1039782B/en unknown
- 1999-09-30 CZ CZ20011144A patent/CZ20011144A3/cs unknown
- 1999-09-30 JP JP2000572253A patent/JP4243792B2/ja not_active Expired - Fee Related
- 1999-09-30 DE DE69938970T patent/DE69938970D1/de not_active Expired - Lifetime
- 1999-09-30 AU AU64078/99A patent/AU6407899A/en not_active Abandoned
- 1999-09-30 AT AT99951690T patent/ATE399179T1/de not_active IP Right Cessation
- 1999-09-30 WO PCT/US1999/022819 patent/WO2000018795A2/en not_active Ceased
- 1999-09-30 MY MYPI99004243A patent/MY139226A/en unknown
- 1999-09-30 PL PL348595A patent/PL201881B1/pl not_active IP Right Cessation
- 1999-09-30 BR BR9914116-7A patent/BR9914116A/pt not_active Application Discontinuation
- 1999-09-30 NZ NZ510600A patent/NZ510600A/en not_active IP Right Cessation
- 1999-09-30 TR TR2001/01482T patent/TR200101482T2/xx unknown
- 1999-12-22 TW TW094123744A patent/TWI285648B/zh active
-
2000
- 2000-01-22 SA SA00200872A patent/SA00200872B1/ar unknown
-
2001
- 2001-03-22 IL IL142216A patent/IL142216A/en not_active IP Right Cessation
- 2001-03-29 NO NO20011613A patent/NO325839B1/no not_active IP Right Cessation
-
2006
- 2006-08-23 JP JP2006227215A patent/JP2007001984A/ja active Pending
-
2007
- 2007-10-26 JP JP2007279673A patent/JP4235984B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9914116A (pt) | Composições e métodos para imunoterapia especìfica de wt1 | |
| BRPI0409879A (pt) | composições e métodos para imunoterapia especìfica wt1 | |
| ATE429442T1 (de) | Zusammensetzungen und verfahren zur wt1- spezifischen immuntherapie | |
| DE60135005D1 (de) | Verbindungen und methoden zur wt1-spezifischen immuntherapie | |
| BR0113235A (pt) | Composições e métodos para a terapia e a diagnose de malignidades associadas com her-2/neu | |
| BR0112542A (pt) | Composições e métodos papa a terapia e a diagnose de câncer ovariano | |
| BR9916207A (pt) | Composições e métodos para terapia e diagnósticode câncer ovariano | |
| IL87885A (en) | Pharmaceutical compositions having antiprogestational and anti-estrogenic activities for the treatment of hormone- dependent tumors | |
| ATE530577T1 (de) | Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren | |
| DE69838979D1 (de) | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren | |
| ATE296839T1 (de) | Antikörper zur krebsbehandlung und -diagnose | |
| BR0107643A (pt) | Composições e processos para a terapia e diagnóstico de c ncer de próstata | |
| NO963918D0 (no) | Isolerte peptider avledet fra tumor-rejeksonsforlöperen MAGE-2, samt anvendelse derav | |
| EP0552296A4 (en) | Mouse monoclonal antibodies | |
| BR0314369A (pt) | Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado | |
| SE8700467D0 (sv) | Cross-protective human monoclonal antibody compositions | |
| DK0500602T3 (da) | Middel til neutralisering af til tumorceller knyttet prokoagulantaktivitet | |
| DK0454782T3 (da) | Cancer-beslægtet haptaglobin (Hpr.) | |
| AR004360A1 (es) | Composiciones farmaceuticas para la terapia de carcinomas del epitelio plano y un agente para ser empleado en estas composicines farmaceuticas. | |
| BR0111024A (pt) | Composições e métodos para a terapia e diagnóstico de câncer de mama | |
| ATE475710T1 (de) | Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs | |
| SE8304111D0 (sv) | Amino derivatives of benzylidene-pyrrolo(2,1-b)-quinazolines and benzylidene-pyrido(2,1-b)quinazolines | |
| UA30435A (uk) | Спосіб визначення онкологічного маркеру в сироватці крові |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 10 (VIII E IX), 11, 13 E 24 DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |